loxo-292
loxo-292: sourced relationships with 1 company · 1 clinical trial tracked.
loxo-292 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect loxo-292 to LOXO; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could loxo-292 → LOXO affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| LOXO ONCOLOGY, INC. (LOXO) | Phase 1 |
Clinical Trial Registry Records (1)
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Primary endpoint: Phase 1: Maximum Tolerated Dose (MTD)
Interventionalopen857 targetStarted 2017-05Completion 2027-0250 sites · Australia, Canada, Denmark, France…Eli Lilly and Company
Frequently asked questions
Which companies have sourced relationships with loxo-292?
loxo-292 has dated SEC/FDA relationship records for LOXO ONCOLOGY, INC..
How many clinical trials involve loxo-292?
BioSniper tracks 1 clinical trial involving loxo-292.